Update on Full Year Results

Kromek Group PLC

30 September 2024

 

30 September 2024

Kromek Group plc

("Kromek" or the "Group")

Update on Full Year Results

Kromek (AIM: KMK), a leading developer of radiation and bio-detection technology solutions for the advanced imaging and CBRN detection segments, gives notice that, further to the Group's trading update of 29 May 2024 (the "Trading Update") in which it stated it expected to release its full year results in September 2024, the Group now expects to announce its final results for the year ended 30 April 2024 during the second half of October.

The Group is experiencing increasing commercial and strategic momentum and continues to pursue further initiatives across the business. As noted in the Trading Update, Kromek expects to report positive EBITDA for FY 2024, ahead of market expectations. This reflects an anticipated improvement in gross margin due to the product mix sold combined with the Group exerting continued tight cost control whilst driving operational efficiencies, particularly within its advanced imaging manufacturing process.

Further details will be provided in the Group's final results announcement.

For further information, please contact:

Kromek Group plc
Arnab Basu, CEO  Paul Farquhar, CFO	[phone]
Cavendish Capital Markets Limited (Nominated Adviser and Broker)
Geoff Nash/Giles Balleny/Seamus Fricker - Corporate Finance  Tim Redfern - ECM	[phone]
Michael Johnson/Tamar Cranford-Smith - Sales
Gracechurch Group (Financial PR)
Harry Chathli/Claire Norbury/Henry Gamble	[phone]

Kromek Group plc 

Kromek Group plc is a leading developer of radiation detection and bio-detection technology solutions for the advanced imaging and CBRN detection segments. Headquartered in County Durham, UK, Kromek has manufacturing operations in the UK and US, delivering on the vision of enhancing the quality of life through innovative detection technology solutions.  

The advanced imaging segment comprises the medical, security and industrial markets. Kromek provides its OEM customers with detector components, based on its core cadmium zinc telluride (CZT) platform, to enable better detection of diseases such as cancer and Alzheimer's, contamination in industrial manufacture and explosives in aviation settings.  

In CBRN detection, the Group provides nuclear radiation detection solutions to the global homeland defense and security market. Kromek's compact, handheld, high-performance radiation detectors, based on advanced scintillation technology, are primarily used to protect critical infrastructure and urban environments from the threat of 'dirty bombs'.  

The Group is also developing bio-security solutions in the CBRN detection segment. These consist of fully automated and autonomous systems to detect a wide range of airborne pathogens.  

Kromek is listed on AIM, a market of the London Stock Exchange, under the trading symbol 'KMK'.  

Further information is available at www.kromek.com. 

 

END